Lectus Therapeutics Limited is a UK-based drug discovery and development company, specialising in the discovery and development of best- and first-in-class ion channel therapeutics for urinary bladder disorders, pain and angina.

Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.